Use of the erythromycin breath test for in vivo assessments of cytochrome P4503a activity and dosage individualization

Clinical Pharmacology and Therapeutics

Volumn 70, Issue 4, 2001, Pages 305-310

  Chiou, W L ^a   Hyun Young Jeong, ^a   Wu, T C ^a   Ma, C ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; ERYTHROMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BREATH ANALYSIS; CONTROLLED STUDY; DEMETHYLATION; DISEASE ACTIVITY; DOSE CALCULATION; DRUG ELIMINATION; INDIVIDUALIZATION; METABOLIC CLEARANCE RATE; NONHUMAN; NOTE; PLASMA CLEARANCE; PRIORITY JOURNAL; RAT; REPRODUCIBILITY; SEX DIFFERENCE; TISSUE DISTRIBUTION;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BREATH TESTS; CARBON DIOXIDE; CARBON RADIOISOTOPES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; ERYTHROMYCIN; HUMANS; LIVER; MODELS, CHEMICAL; OXIDOREDUCTASES, N-DEMETHYLATING; P-GLYCOPROTEIN; SEX FACTORS;

EID: 0034750648     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.118857     Document Type: Note

References (39)

1. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450
2. Breath tests as noninvasive assays of P450s
3. Noninvasive tests of CYP3A enzymes
4. In vitro and in vivo drug interactions involving human CYP3A
5. Mdr1 limits CYP3A metabolism in vivo
6. Problems and perspectives of phenotyping for drug-metabolizing enzymes in man
7. Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity
8. Simvastatin does not affect CYP3A activity, quantified by the erythromycin breath test and oral midazolam pharmacokinetics, in healthy male subjects
9. The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics
10. In vivo comparison of putative probes of CYP3A4/5 activity: Erythromycin, dextromethorphan, and verapamil
11. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy man
12. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A
13. Optimizing the erythromycin breath test for use in cancer patients
14. Intersubject and dose-related variability after intravenous administration of erythromycin
15. 14C] formate oxidation in rat liver
16. Measurement of bicarbonate turnover in humans: Applicability to establish energy expenditure
17. [13C]bicarbonate kinetics in humans: Intra- vs. interindividual variations
18. Compartment- and model-independent linear plateau principle drugs during a constant-rate absorption or intravenous infusion
19. 14-erythromycin
20. Interspecies correlation of the pharmacokinetics of erythromycin, oleandomycin, and tylosin
21. Plasma levels of parent drug and metabolites in the intravenous aminopyrine breath test
22. Pharmacokinetics of erythromycin in man
23. Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice
24. Potential role of P-glycoprotein in affecting hepatic metabolism of drugs
25. Elucidation of human amphotericin B pharmacokinetics: Identification of a new potential factor affecting interspecies pharmacokinetic scaling
26. P-glycoprotein: A major determinant of rifampicin-inducible expression of cytochromes P4503A in mice and humans
27. Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene
28. P-glycoprotein-dependent disposition kinetics of tacrolimus: Studies in mdr1a knockout mice
29. Gender effects in pharmacokinetics and pharmacodynamics
30. Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol
31. The phenomenon and rationale of marked dependence of drug concentration on blood sampling site: Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (part I)
32. The phenomenon and rationale of marked dependence of drug concentration on blood sampling site: Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (part II)
33. Pharmacokinetics analysis of bioequivalence trials: Implications for sex-related issues in clinical pharmacology and biopharmaceutics
34. A new model-independent physiological approach to study hepatic drug clearance and its applications
35. Effect of change in blood flow on hemodialysis clearance studied by simple unified organ clearance approach
36. The effect of change in luminal perfusion rate on intestinal drug absorption studied by a simple unified organ clearance approach
37. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians
38. Gender differences in alcohol metabolism: Relationship to liver volume and effect of adjusting for body mass